Vericel (VCEL)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$40.26-6.18%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put VCEL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Operating margin at least 27%: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 23% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskVCEL’s core case rests on strong recent performance, but growth is unverified because earnings history is absent. The desk has no recorded earnings release, so the latest beat or miss cannot be established. VCEL trades at 7× sales versus a 9× peer median, near its 8× historical multiple. The price reflects less growth than our forecast, despite peer multiples implying a price about 16% below where it trades. Our model puts the next-quarter miss probability near 38%. Operating margin’s 27% threshold comparison needs review, not confirmation of a breach. Our read remains provisional.
Trailing returns as of 2026-10-30. VCEL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering VCEL (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare VCEL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VCEL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put VCEL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase MACI revenue growth
20% revenue jump supports MACI growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase MACI revenue growth
20% revenue jump supports MACI growth objective.
Advances: Achieve high revenue and profit growth
Forecasting strong revenue growth aligns with profit objectives.
Advances: Achieve high revenue and profit growth
Raising guidance indicates strong profit growth potential.
Advances: Expand Burn Care revenue
BARDA award enhances Burn Care revenue expansion.
Advances: Achieve high revenue and profit growth
FDA approval supports high revenue and profit growth.
Advances: Increase MACI revenue growth
Sales force expansion expected to boost MACI revenue.
Threatens: Expand Burn Care revenue
Waning Burn Care revenue poses a challenge.